NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 69 filers reported holding NURIX THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $411,298 | -29.7% | 52,328 | -10.7% | 0.00% | -100.0% |
| Q2 2023 | $585,185 | +140.5% | 58,577 | +113.8% | 0.00% | – |
| Q1 2023 | $243,312 | -19.1% | 27,400 | +0.0% | 0.00% | – |
| Q4 2022 | $300,753 | -20.0% | 27,391 | -5.1% | 0.00% | – |
| Q3 2022 | $376,000 | +90.9% | 28,850 | +84.7% | 0.00% | – |
| Q2 2022 | $197,000 | -3.0% | 15,619 | +7.9% | 0.00% | – |
| Q1 2022 | $203,000 | -48.7% | 14,474 | +5.7% | 0.00% | – |
| Q4 2021 | $396,000 | -3.6% | 13,695 | -0.0% | 0.00% | – |
| Q3 2021 | $411,000 | +50.5% | 13,698 | +32.8% | 0.00% | – |
| Q2 2021 | $273,000 | -10.8% | 10,313 | +5.0% | 0.00% | – |
| Q1 2021 | $306,000 | -47.6% | 9,826 | -44.7% | 0.00% | – |
| Q4 2020 | $584,000 | – | 17,782 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ponoi II Management, LLC | 561,574 | $16,825,000 | 24.93% |
| Ponoi Management, LLC | 561,573 | $16,825,000 | 14.94% |
| TRV GP III, LLC | 2,422,549 | $72,580,000 | 13.78% |
| Foresite Capital Management IV, LLC | 1,205,798 | $36,126,000 | 5.32% |
| Foresite Capital Management V, LLC | 451,522 | $13,528,000 | 4.20% |
| WestHill Financial Advisors, Inc. | 283,333 | $8,489,000 | 2.62% |
| DAFNA Capital Management LLC | 306,320 | $9,177,000 | 2.44% |
| Bain Capital Life Sciences Investors, LLC | 1,284,314 | $38,478,000 | 2.39% |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | 571,212 | $17,113,000 | 2.02% |
| Redmile Group, LLC | 3,093,077 | $92,669,000 | 1.62% |